Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma

Chinese Journal of Cancer Research

Volumn 27, Issue 3, 2015, Pages 309-317

  Tang, Zhijian ^a   Chang, Xiaohong ^a   Ye, Xue ^a   Li, Yi ^a   Cheng, Hongyan ^a   Cui, Heng ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Advanced epithelial ovarian cancer (EOC); CA125; Human epididymis protein 4 (HE4); Optimal cytoreduction

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; COLON RESECTION; COLOSTOMY; CYTOREDUCTIVE SURGERY; ENZYME IMMUNOASSAY; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; INTESTINE ANASTOMOSIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MESENTERY DISEASE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OMENTECTOMY; OUTCOME ASSESSMENT; PERITONEUM CANCER; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIMARY TUMOR; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SIGMOIDECTOMY; SMALL INTESTINE RESECTION; UTERINE TUBE CARCINOMA;

EID: 84940203061     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2015.06.01     Document Type: Article

References (21)

1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Accessed in 2015. Available online: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
4. Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol 2010;119:259-64.
5. Chi DS, Venkatraman ES, Masson V, et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:227-31.
6. Chi DS, Zivanovic O, Palayekar MJ, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 2009;112:6-10.
7. Vorgias G, Iavazzo C, Savvopoulos P, et al. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol 2009;112:11-5.
8. Angioli R, Plotti F, Capriglione S, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 2013;128:579-83.
9. Barlow TS, Przybylski M, Schilder JM, et al. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 2006;16:496-500.
10. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9.
11. Bast RC Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 Suppl 3:274-81.
12. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
13. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53.
14. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8.
15. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-9.
16. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
17. Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007;105:211-7.
18. Bristow RE. Predicting “unresectable” ovarian cancer: Taking aim at a moving target. Gynecol Oncol 2006;100:449-50.
19. Salani R, Axtell A, Gerardi M, et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008;108:271-5.
20. Ferrandina G, Sallustio G, Fagotti A, et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer 2009;101:1066-73.
21. Suidan RS, Ramirez PT, Sarasohn DM, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 2014;134:455-61.